Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

L'Express

May 14, 2020

ABX464, une nouvelle molécule prometteuse pour lutter contre le Covid-19

Les Echos

May 14, 2020

Coronavirus : ces biotech françaises qui testent des médicaments

Journal Med

May 14, 2020

COVID-19: ABX464 hemmt Replikation von SARS-CoV-2 im Atemwegsepithelmodell

4 investors

May 14, 2020

Abivax Aktie stark im Plus nach News zu Covid-19-Medikamentenkandidaten

Wirtschafts Woche

May 14, 2020

Abivax – Neue Dreifach-Hoffnung im Kampf gegen Corona

  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn